[1]刘广峰,洪婷婷,苗森,等.玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究[J].眼科新进展,2017,37(7):658-661.[doi:10.13389/j.cnki.rao.2017.0167]
　LIU Guang-Feng,HONG Ting-Ting,MIAO Sen,et al.Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(7):658-661.[doi:10.13389/j.cnki.rao.2017.0167]
点击复制

玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞继发非缺血性黄斑水肿的临床对照研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年7期
页码:
658-661
栏目:
应用研究
出版日期:
2017-07-05

文章信息/Info

Title:
Comparison of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion
作者:
刘广峰; 洪婷婷; 苗森; 孟忻; 王华; 贾羽颂; 付秀稳; 汪军
100029　北京市，首都医科大学附属北京安贞医院眼科
Author(s):
LIU Guang-Feng; HONG Ting-Ting; MIAO Sen; MEN Xin; WANG Hua; JIA Yu-Song; FU Xiu-Wen; WANG Jun
Department of Ophthalmology，Beijing Anzhen Hospital，Capital Medical University，Beijing 100029，China
关键词:
康柏西普; 视网膜分支静脉阻塞; 黄斑水肿; 视网膜光凝
Keywords:
conbercept; branch retinal vein occlusion; macular edema; macular photocoagulation
分类号:
R774
DOI:
10.13389/j.cnki.rao.2017.0167
文献标志码:
A
摘要:
目的　探讨玻璃体内注射康柏西普与黄斑区光凝治疗视网膜分支静脉阻塞（branch retinal vein occlusion，BRVO）继发非缺血性黄斑水肿的疗效和安全性。方法　回顾分析临床确诊的BRVO继发非缺血性黄斑水肿患者50例（50眼），依据手术情况将患者分为2组，康柏西普组26例（26眼）患者接受按需治疗的玻璃体内注射，光凝组24例（24眼）患者接受标准的黄斑区格栅样光凝治疗黄斑水肿。2组分别于术后1周、1 个月、2个月、3 个月进行复查，观察患者的最佳矫正视力（best-corrected visual acuity，BCVA）和黄斑中心凹厚度（central macular thickness，CMT）的变化。对比分析2组患眼治疗前后BCVA、CMT 的变化，并观察眼部和全身并发症的发生情况。结果　治疗前2组患者的BCVA差异无统计学意义（P>0.05）。康柏西普组和光凝组治疗后1周、1个月、2个月、3个月时BCVA均较治疗前提高，差异均有统计学意义（均为P<0.05）；康柏西普组与光凝组治疗后1周、1个月、2个月、3个月时组间比较均较高，差异均有统计学意义（均为P<0.05）。术后3个月，康柏西普组18眼（69.23%）视力提高2行以上；光凝组8眼（33.33%）视力提高2行以上。治疗前2组患者的CMT组间比较，差异无统计学意义（P>0.05）。康柏西普组和光凝组治疗后1周、1个月、2个月、3个月时CMT均较术前减小，差异均有统计学意义（均为P<0.05）。康柏西普组与光凝组治疗后1周、1个月、2个月、3个月时2组间CMT比较均较小，差异均有统计学意义（均为P<0.05）。康柏西普组首次注药后随访3个月，11眼行重复注射。其中1个月后CMT>250 μm重复注射2眼，2个月后重复注射7眼，3个月后重复注射2眼。随访期间50眼均未发生与药物、玻璃体内注射相关的全身不良反应。注射后出现局部球结膜下出血7眼。结论　康柏西普治疗BRVO继发的非缺血性黄斑水肿术后视力提高的程度和黄斑区视网膜水肿减轻的程度均优于黄斑区格栅样光凝治疗。
Abstract:
Objective　To assess the clinical effects and safety of intravitreal injection of conbercept and macular photocoagulation for non-ischemic macular edema secondary to branch retinal vein occlusion （BRVO）.Methods　A total of 50 patients （50 eyes） with non-ischemic macular edema following BRVO were retrospectively analyzed.Patients were divided into 2 groups：ICI group （26 eyes） received intravitreal injection of conbercept，laser group （24 eyes） received standard-of-care grid laser for macular edema.The best-corrected visual acuity （BCVA） and central macular thickness （CMT） were observed before and 1 week，1 month，2 months and 3 months after treatment.Then，the changes in pre-treatment and post-treatment were compared，and the related complications were recorded.Results　The difference of BCVA before treatment was not significant between two groups（P>0.05）.BCVA at 1 week，1 month，2 months and 3 months after treatment in two groups were all improved，the differences were statistically significant compared with before treatment （all P<0.05），and the differences were statistically significant between two groups after treatment （all P<0.05）.At 3 months after treatment，BCVA of 18 patients （69.23%） in ICI group and 8 patients （33.33%） in ICI group improved 2 lines.The difference of CMT before treatment was not significant between two groups（P>0.05），CMT at 1 week，1 month，2 months and 3 months after treatment in two groups were all decreased，the differences were statistically significant compared with before treatment （all P<0.05），and the differences were statistically significant between two groups after treatment （all P<0.05）.13 eyes received repeat intravitreal injection in ICI group，including 2 eyes at 1 month，7 eyes at 2 months with CMT>250 μm，and 3 eyes at 3 months.No severe side effect related with drug and intravitreal injection occurred in the two groups.Conclusion　Mean BCVA change and CMT change are significantly greater in the intravitreal injection of conbercept than the standard-of-care grid laser group for the macular edema secondary to non-ischemic BRVO.

参考文献/References:

［1］　ROGERS S，MCINTOSH RL，CHEUNG N，LIM L，WANG JJ，MITCHELL P，et al.The prevalence of retinal vein occlusion：pooled data from population studies from the United States，Europe，Asia，and Australia［J］.Ophthalmology，2010，117（2）：313-319.
［2］　MITCHELL P，SMITH W，CHANG A.Prevalence and associations of retinal vein occlusion in Australia［J］.Arch Ophthalmol，1996，114（10）：1243-1247.
［3］　KLEIN R，MOSS SE，MEUER SM，KLEIN BE.The 15-year cumulative incidence of retinal vein occlusion：the Beaver Dam Eye Study［J］.Arch Ophthalmol，2008，126（4）：513-518.
［4］　ROGERS SL，MCINTOSH RL，LIM L，MITCHELL P，CHEUNG N，KOWALSKI JW，et al.Natural history of branch retinal vein occlusion：an evidence-based systematic review［J］.Ophthalmology，2010，117（6）：1094-1101.
［5］　PATZ A.Argon laser photocoagulation for macular edema in branch vein occlusion［J］.Am J Ophthalmol，1984，98（3）：271-282.
［6］　FINKELSTEIN D.Argon laser photocoagulation for macular edema in branch vein occlusion［J］.Ophthalmology，1986，93（7）：975-977.
［7］　SCOTT IU，IP MS，VANVELDHUISEN PC，ODEN NL，BLODI BA，FISHER M，et al.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion：the Standard Care vs Corticosteroid for Retinal Vein Occlusion （SCORE） study report 6［J］.Arch Ophthalmol，2009，127（9）：1115-1128.
［8］　HAYREH SS.Prevalent misconceptions about acute retinal vascular occlusive disorders［J］.Prog Retin Eye Res，2005，24（4）：493-519.
［9］　PARODI MB，DI STEFANO G，RAVALICO G.Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion［J］.Retina，2008，28（1）：97-102.
［10］　CAMPOCHIARO PA，HEIER JS，FEINER L，GRAY S，SAROJ N，RUNDLE AC，et al.Ranibizumab for macular edema following branch retinal vein occlusion：six-month primary end point results of a phase III study［J］.Ophthalmology，2010，117（6）：1102-1112.
［11］　CLARK WL，BOYER DS，HEIER JS，BROWN DM，HALLER JA，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion［J］.Ophthalmology，2016，123（2）：330-336.
［12］　VARMA R，BRESSLER NM，SUNER I，LEE P，DOLAN CM，WARD J，et al.Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion［J］.Ophthalmology，2012，119（10）：2108-2118.
［13］　BROWN DM，CAMPOCHIARO PA，BHISITKUL RB，HO AC，GRAY S，SAROJ N，et al.Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion：12-month outcomes of a phase III study［J］.Ophthalmology，2011，118（8）：1594-1602.
［14］　CAMPOCHIARO PA，CLARK WL，BOYER DS，HEIER JS，BROWN DM，VITTI R，et al.Intravitreal aflibercept for macular edema following branch retinal vein occlusion［J］.Ophthalmology，2015，122（3）：538-544.
［15］　TAN MH，MCALLISTER IL，GILLIES ME，VERMA N，BANERJEE G，SMITHIES LA，et al.Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion［J］.Am J Ophthalmol，2014，157（1）：237-247.
［16］　CAMPOCHIARO PA，WYKOFF CC，SINGER M，JOHNSON R，MARCUS D，YAU L，et al.Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion［J］.Ophthalmology，2014，121（12）：2432-2442.
［17］　王琛，闻毅颐，李东豪.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性［J］.眼科新进展，2016，36 （5）：471-473.
WANG C，WEN YY，LI DH.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion［J］.Rec Adv Ophthalmol，2016，36 （5）：471-473.
［18］　张菁，蔡小军，陈晓敏，郑恬，郭别川，韩芳芳，等.玻璃体内注射康柏西普联合视网膜激光光凝治疗视网膜分支静脉阻塞继发黄斑水肿疗效观察［J］.中华眼底病杂志，2015，31（1）：22-26.
ZHANG Q，CAI XJ，CHEN XM，ZHENG T，GUO BC，HAN FF et al.A prospective randomized clinical trial on intravitreous injection of Conbercept combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion［J］.Chin J Ocul Fundus Dis，2015，31（1）：22-26.
［19］　CAMPOCHIARO PA，HAFIZ G，MIR TA，SCOTT AW，SOLOMON S，ZIMMER-GALLER I，et al.Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion［J］.Ophthalmology，2015，122（7）：1426-1437.
［20］　郑红梅，邢怡桥，陈长征，易佐慧子.玻璃体内注射抗血管内皮生长因子单克隆抗体ranibizumab联合格栅样激光光凝治疗视网膜分支静脉阻塞合并黄斑水肿疗效观察［J］.中华眼底病杂志，2012，28（5）：472-476.
ZHENG HM，XING YQ，CHEN CZ，YI ZHZ.Combined intravitreal ranibizumab and grid laser photocoagulation for branch retinal vein occlusion with macular edema［J］.Chin J Ocul Fundus Dis，2012，28（5）：472-476.

相似文献/References:

[1]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[2]曹婷婷,陈桂芬,范玉香,等.视网膜分支静脉阻塞合并黄斑水肿不同治疗方法的疗效观察[J].眼科新进展,2014,34(8):772.[doi:10.13389/j.cnki.rao.2014.0213]
　CAO Ting-Ting,CHEN Gui-Fen,FAN Yu-Xiang,et al.Clinical observation in different treatment methods of branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2014,34(7):772.[doi:10.13389/j.cnki.rao.2014.0213]
[3]傅维娜,陈梅珠,王云鹏. Lucentis联合视网膜光凝治疗视网膜分支静脉阻塞继发黄斑水肿[J].眼科新进展,2015,35(3):270.[doi:10.13389/j.cnki.rao.2015.0072]
　FU Wei-Na,CHEN Mei-Zhu,WANG Yun-Peng. Intravitreal injection with lucentis combined with local retinal photocoagulation for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(7):270.[doi:10.13389/j.cnki.rao.2015.0072]
[4]董宁,汤欣,肖林,等. 视网膜分支静脉阻塞患者急性期和恢复期血浆同型半胱氨酸水平的变化[J].眼科新进展,2015,35(4):368.[doi:10.13389/j.cnki.rao.2015.0099]
　DONG Ning,TANG Xin,XIAO Lin,et al. Acute and convalescent changes in plasma homocysteine concentrations in branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2015,35(7):368.[doi:10.13389/j.cnki.rao.2015.0099]
[5]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(7):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[6]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(7):172.[doi:10.13389/j.cnki.rao.2016.0047]
[7]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(7):471.[doi:10.13389/j.cnki.rao.2016.0126]
[8]王玮,徐玲娟,蔡苏博,等.角膜基质及结膜下单次注射康柏西普治疗角膜新生血管的疗效及安全性[J].眼科新进展,2016,36(8):725.[doi:10.13389/j.cnki.rao.2016.0192]
　WANG Wei,XU Lin-Juan,CAI Su-Bo,et al.Efficacy and safety of one dose intrastromal and subconjunctival conbercept injection for corneal neovascularization[J].Recent Advances in Ophthalmology,2016,36(7):725.[doi:10.13389/j.cnki.rao.2016.0192]
[9]史志洁,张金嵩,吕晓贝.玻璃体内注射康柏西普联合手术治疗伴玻璃体积血的新生血管性青光眼[J].眼科新进展,2016,36(8):751.[doi:10.13389/j.cnki.rao.2016.0200]
　SHI Zhi-Jie,ZHANG Jin-Song,LV Xiao-Bei.Intravitreal injection of conbercept and surgical treatment for neovascular glaucoma combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(7):751.[doi:10.13389/j.cnki.rao.2016.0200]
[10]罗顺利,许泽广,梁春正.复合式小梁切除术联合康柏西普治疗新生血管性青光眼[J].眼科新进展,2016,36(11):1076.[doi:10.13389/j.cnki.rao.2016.0287]
　LUO Shun-Li,XU Ze-Guang,LIANG Chun-Zheng.Compound trabeculectomy with conbercept for neovascular glaucoma[J].Recent Advances in Ophthalmology,2016,36(7):1076.[doi:10.13389/j.cnki.rao.2016.0287]
[11]林国乔,郑德志,陈伟奇.康柏西普治疗视网膜分支静脉阻塞(BRVO)继发黄斑水肿的临床研究[J].眼科新进展,2018,38(11):1055.[doi:10.13389/j.cnki.rao.2018.0248]
　LIN Guo-Qiao,ZHENG De-Zhi,CHEN Wei-Qi.Clinical outcomes of intravitreal Conbercept injection for macular edema secondary to branch retinal vein occlusion[J].Recent Advances in Ophthalmology,2018,38(7):1055.[doi:10.13389/j.cnki.rao.2018.0248]

备注/Memo

备注/Memo:
首都医科大学附属北京安贞医院院长科技发展基金（编号：2013F03）
更新日期/Last Update: 2017-08-02